Vous êtes ici

2019

2019

  1. Vukusic S, Rollot F, Casey R, Pique J, Marignier R, Mathey G, Edan G, Brassat D, Ruet A, De Sèze J, Maillart E, Zéphir H, Labauge P, Derache N, Lebrun-Frenay C, Moreau T, Wiertlewski S, Berger E, Moisset X, Rico-Lamy A, Stankoff B, Bensa C, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Vaillant M, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Tourbah A, Guennoc AM, Hankiewicz K, Patry I, Nifle C, Maubeuge N, Labeyrie C, Vermersch P, Laplaud DA; OFSEP Investigators. Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France. JAMA Neurol. 2019. doi: 10.1001/jamaneurol.2019.2670. IF 2018 = 12.321; 5YIF = 10.791

  2. Binamé F, Pham-Van LD, Spenlé C, Jolivel V, Birmpili D, Meyer LA, Jacob L, Meyer LMensah-Nyagan AG, Po C, Van der Heyden M, Roussel G, Bagnard D. Disruption of Sema3A/Plexin-A1 inhibitory signalling in oligodendrocytes as a therapeutic strategy to promote remyelination. EMBO Mol Med. 2019;doi: 10.15252/emmm.201910378. IF 2018 = 10.62; 5YIF = 10.38

  3. Meyer L, Taleb O, Patte-Mensah CMensah-Nyagan AG. Neurosteroids and neuropathic pain management: Basic evidence and therapeutic perspectives. Front Neuroendocrinol. 2019:100795. doi: 10.1016/j.yfrne.2019.100795. IF 2018 = 7.852; 5YIF = 9.421

  4. Laplaud DA, Casey R, Barbin L, Debouverie M, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Lubetzki C, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Wahab A, Labauge P, Magy L, Defer G, Guennoc AM, Maubeuge N, Labeyrie C, Patry I, Nifle C, Casez O, Michel L, Rollot F, Leray E, Vukusic S, Foucher Y; SFSEP and OFSEP groups. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. Neurology. 2019;93:e635-e646. doi: 10.1212/WNL.0000000000007938. IF 2018 = 8.689; 5YIF = 9.025

  5. Cobo-Calvo A, Sepúlveda M, Rollot F, Armangué T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Thouvenot E, Bourre B, Montcuquet A, Cohen M, Deschamps R, Solà-Valls N, Llufriu S, De Seze J, Blanco Y, Vukusic S, Saiz A, Marignier R. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflammation. 2019;16:134. doi: 10.1186/s12974-019-1525-1. IF 2018 = 5.7; 5YIF = 6.016

  6. Kremer L, Taleb O, Boehm N, Mensah-Nyagan AG, Trifilieff E, de Seze J, Brun S. FTY720 controls disease severity and attenuates sciatic nerve damage in chronic experimental autoimmune neuritis. J Neuroinflammation. 2019; doi: 10.1186/s12974-019-1441-4. IF 2018 = 5.193; 5YIF = 5.763

  7. Pfaff L, Lamy J, Noblet V, Gounot D, Chanson JB, de Seze J, Blanc F. Emotional disturbances in multiple sclerosis: A neuropsychological and fMRI study. Cortex. 2019; doi: 10.1016/j.cortex.2019.02.017. IF 2018 = 4.275; 5YIF = 4.716

  8. Vukusic S, Casey R, Rollot F, Brochet B, Pelletier J, Laplaud DA, De Sèze J, Cotton F, Moreau T, Stankoff B, Fontaine B, Guillemin F, Debouverie M, Clanet M; the OFSEP Investigators. Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France. Mult Scler J. 2019; doi: 10.1177/1352458518815602. IF 2018 = 5.649; 5YIF = 4.862

  9. Ciron J, Cobo-Calvo A, Audoin B, Bourre B, Brassat D, Cohen M, Collongues N, Deschamps R, Durand-Dubief F, Laplaud D, Maillart E, Papeix C, Zephir H, Bereau M, Brochet B, Carra-Dallière C, Derache N, Gagou-Scherer C, Henry C, Kerschen P, Mathey G, Maubeuge N, Maurousset A, Montcuquet A, Moreau T, Prat C, Taithe F, Thouvenot E, Tourbah A, Rollot F, Vukusic S, Marignier R. Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. Mult Scler J. 2019 1352458519849511. doi: 10.1177/1352458519849511. IF 2018 = 5.649; 5YIF = 4.862

  10. Collongues N, Ayme-Dietrich E, Monassier L, de Seze J. Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options. Drugs. 2019; doi: 10.1007/s40265-018-1039-7. IF 2018 = 4.993; 5YIF = 4.647

  11. de Seze J. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder. Curr Opin Neurol. 2019; doi: 10.1097/WCO.0000000000000650. IF 2018 = 4.647; 5YIF = 4.579

  12. Barclay K, Carruthers R, Traboulsee A, Bass AD, LaGanke C, Bertolotto A, Boster A, Celius EG, de Seze J, Cruz DD, Habek M, Lee JM, Limmroth V, Meuth SG, Oreja-Guevara C, Pagnotta P, Vos C, Ziemssen T, Baker DP, Wijmeersch BV. Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. Front Neurol. 2019; doi: 10.3389/fneur.2019.00253. IF 2018 = 2.635; 5YIF = 3.233 (Review)

  13. Ayrignac X, Rigau V, Lhermitte B, Vincent T, de Champfleur NM, Carra-Dalliere C, Charif M, Collongues N, de Seze J, Hebbadj S, Ahle G, Oesterlé H, Cotton F, Durand-Dubief F, Marignier R, Vukusic S, Taithe F, Cohen M, Guennoc AM, Kerbrat A, Edan G, Carsin-Nicol B, Allou T, Sablot D, Thouvenot E, Ruet A, Magy L, Boncoeur-Martel MP, Labauge P, Kremer S. Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions. J Neurol. 2019; doi: 10.1007/s00415-019-09328-7. IF 2018 = 4.204; 5YIF = 3.999

  14. Cobo-Calvo A, Sepúlveda M, d'Indy H, Armangué T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Thouvenot E, Montcuquet A, Deschamps R, Solà-Valls N, Llufriu S, Blanco Y, de Seze J, Vukusic S, Saiz A, Marignier R; OFSEP Group; REEM Group. Correction to: Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. J Neurol. 2019; doi: 10.1007/s00415-019-09215-1. IF 2018 = 4.204; 5YIF = 3.999

  15. Lejri I, Grimm A, Hallé F, Abarghaz M, Klein C, Maitre M, Schmitt M, Bourguignon JJ, Mensah-Nyagan AG, Bihel F, Eckert A. TSPO Ligands Boost Mitochondrial Function and Pregnenolone Synthesis. J Alzheimers Dis. 2019. doi: 10.3233/JAD-190127. IF 2018 = 3.517; 5YIF = 3.908

  16. Maillart E, Labauge P, Cohen M, Maarouf A, Vukusic S, Donzé C, Gallien P, De Sèze J, Bourre B, Moreau T, Louapre C, Mayran P, Bieuvelet S, Vallée M, Bertillot F, Klaeylé L, Argoud AL, Zinaï S, Tourbah A. MSCopilot, a new multiple sclerosis self-assessment digital solution: results of a comparative study versus standard tests. Eur J Neurol. 2019. doi: 10.1111/ene.14091. IF 2018 = 4.387; 5YIF = 3.900

  17. El Khoury Y, Collongues N, De Sèze J, Gulsari V, Patte-Mensah C, Marcou G, Varnek A, Mensah-Nyagan AG, Hellwig P. Serum-based differentiation between multiple sclerosis and amyotrophic lateral sclerosis by Random Forest classification of FTIR spectra. Analyst. 2019; 7;144(15):4647-4652. doi: 10.1039/c9an00754g. IF 2018 = 4.019; 5YIF = 3.857

  18. Combès B, Monteau L, Bannier E, Callot V, Labauge P, Ayrignac X, Carra Dallière C, Pelletier J, Maarouf A, de Seze J, Collongues N, Barillot C, Edan G, Ferré JC, Kerbrat A; EMISEP study group. Measurement of magnetization transfer ratio (MTR) from cervical spinal cord: Multicenter reproducibility and variability. J Magn Reson Imaging. 2019; doi: 10.1002/jmri.26537. IF 2018 = 3.732; 5YIF = 3.57

  19. Bigaut K, Achard S, Hemmert C, Baloglu S, Kremer L, Collongues N, De Sèze J, Kremer S. Resting-state functional MRI demonstrates brain network reorganization in neuromyelitis optica spectrum disorder (NMOSD). PLoS One. 2019; doi: 10.1371/journal.pone.0211465. IF 2018 = 2.776; 5YIF = 3.337

  20. Bigaut K, De Seze J, Collongues N. Ocrelizumab for the treatment of multiple sclerosis. Expert Rev Neurother. 2019; doi: 10.1080/14737175.2019.1561284. IF 2018 = 3.453; 5YIF = 3.144

  21. González SL, Meyer L, Raggio MC, Taleb O, Coronel MF, Patte-Mensah C, Mensah-Nyagan AG. Allopregnanolone and Progesterone in Experimental Neuropathic Pain: Former and New Insights with a Translational Perspective. Cell Mol Neurobiol. 2019; doi: 10.1007/s10571-018-0618-1. IF 2018 = 3.811; 5YIF = 3.126 Review

  22. Vukusic S, Brassat D, de Seze J, Izquierdo G, Lysandropoulos A, Moll W, Vanopdenbosch L, Arque MJ, Kertous M, Rufi P, Oreja-Guevara C. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD). Mult Scler Relat Disord. 2019; doi: 10.1016/j.msard.2019.01.019. IF 2018 = 2.725; 5YIF = 2.815

  23. Codjia P, Ayrignac X, Carra-Dalliere C, Cohen M, Charif M, Lippi A, Collongues N, Corti L, De Seze J, Lebrun C, Vukusic S, Durand-Dubief F, Labauge P; SFSEP and OFSEP. Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases. Mult Scler Relat Disord. 2019; doi: 10.1016/j.msard.2018.12.022. IF 2018 = 2.725; 5YIF = 2.815

  24. Vermersch P, De Sèze J, Clavelou P, Durand-Dubief F, Maillart E, Mekies C, Moreau T, Papeix C, Tourbah A, Labauge P.Expert opinion: Criteria for second-line treatment failure in patients with multiple sclerosis. Mult Scler Relat Disord. 2019;36:101406. doi: 10.1016/j.msard.2019.101406. IF 2018 = 2.725; 5YIF = 2.815

  25. Miller AE, Vermersch P, Kappos L, Comi G, Freedman MS, Oh J, de Seze J, Truffinet P, Benamor M, Purvis A, Wolinsky JS; TOPIC study group. Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study. Mult Scler Relat Disord. 2019;33:131-138. doi: 10.1016/j.msard.2019.05.014. IF 2018 = 2.725; 5YIF = 2.815